• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® PROPATEN® VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® PROPATEN® VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT Back to Search Results
Catalog Number HT066080
Device Problem Microbial Contamination of Device (2303)
Patient Problems Wound Dehiscence (1154); Bacterial Infection (1735); Fever (1858); Inflammation (1932)
Event Date 12/05/2023
Event Type  Injury  
Manufacturer Narrative
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H6 evaluation codes investigation findings c19 belongs to the product history review: a review of the manufacturing records indicated the lots met all pre-release specifications (manufacturing/packaging/boxing/sterilization).H6 evaluation codes type of investigation b13: additional information in regard to the event of the case was requested from the physician.The provided additional information is captured in the event description in section b5.H3: other code: the medical device returned to a third party for further investigation.The analysis report was shared with gore and is being evaluated appropriately.Further investigation is being conducted and will be included in the final report.Heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event Description
It was reported to gore that the patient underwent surgical treatment for a critical limb ischemia with a gore® propaten® vascular graft ¿ thin-walled removable ringed.It was stated that the vascular graft was implanted on (b)(6) 2023, as a femoro-popliteal bypass to treat a critical limb ischemia.Since (b)(6), 2023, the patient has presented with fever, scar disunion disunity of the scar, and the appearance of an inflammatory syndrome.The bypass scar was disunited with a serous ooze.On (b)(6) 2023, after about eight months, the prosthesis was explanted due to a bacterial infection.The gore device was replaced with an allograft.The patient was discharged home on (b)(6), 2023, without any complications.Further information revealed that the infection is probably linked to a vascular surgery, but not to the implant procedure.
 
Manufacturer Narrative
B5 describe event or problem updated.
 
Event Description
It was reported to gore that the patient underwent surgical treatment for a critical limb ischemia with a gore® propaten® vascular graft ¿ thin-walled removable ringed.It was stated that a vascular graft (sn (b)(6)) was implanted on (b)(6) 2023, as a femoro-popliteal bypass to treat a critical limb ischemia.Later the proximal anastomosis obliterated, therefore, on (b)(6) 2023, a further gore® propaten® vascular graft ((b)(6)) was implanted.During this procedure bacteria have been introduced and wound dehiscence due to infection was diagnosed (b)(6) 2023.The patient has presented with fever, dehiscence of the bypass scar with a serous secretion and inflammatory syndrome, requiring hospitalization.Imaging confirmed infection of the grafts.Samples taken were positive to staphylococcus epidermis, corynebacterium tuberculostearicum and staphylococcus aureus.The anastomoses were stenosed and the graft was thrombosed due to persistent infection.Therefore, on (b)(6) 2023, both devices were explanted and were replaced with an allograft.The patient recovered without sequelae and was discharged home on (b)(6) 2023.There was no preexisting infection and the physician stated that the infection was related to the implant procedure of propaten ((b)(6)).
 
Manufacturer Narrative
Explant evaluation: the graft fragment was returned to gepromed for investigation.Submitted in formalin was a gore® propaten® vascular graft ¿ thin-walled removable ringed fragment.The scope and results of the investigation were summarized, and a report was submitted to w.L.Gore & associates.An explant scientist at w.L.Gore & associates reviewed the report.The graft fragment was reported to measure 370 mm in length, and both ends were transected.The abluminal surface appeared to be stained light tan to dark brown, and the blue alignment marks were faintly visible.The rings appeared to be displaced at the mid-body of the graft fragment.The lumens at extremity a and b of the fragment appeared to be open.Extremity a and extremity b both appeared to be partially flattened, transected, and removable rings were absent in these areas.Extremity b appeared to have a jagged edge.A blue monofilament was present at extremity b.No saline patency test was noted to have been performed, therefore the patency of the graft fragment could not be confirmed based on the analysis or images provided.Material disruptions (e.G., transections) were consistent with those caused by surgical instrumentation (e.G., scalpel, scissors), likely used during a surgical procedure.Based on the explant scientist¿s review of the gepromed report, no additional analysis is requested.No information was provided to confirm the presence or absence of the reported infection and no determination can be made from the provided information.In the instruction for use for the gore® propaten® vascular graft the following is stated: adverse events: potential device or procedure-related adverse events.Complications which may occur in conjunction with the use of any vascular prosthesis and/or vascular or related procedures include but are not limited to: infection.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® PROPATEN® VASCULAR GRAFT
Type of Device
PROSTHESIS, VASCULAR GRAFT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL WEST B/P
1505 n. fourth street
flagstaff AZ 86004
Manufacturer Contact
gunter marte
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key18569762
MDR Text Key333552385
Report Number2017233-2024-04561
Device Sequence Number1
Product Code DSY
Combination Product (y/n)Y
Reporter Country CodeFR
PMA/PMN Number
K062161
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 04/08/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberHT066080
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 01/03/2024
Initial Date FDA Received01/24/2024
Supplement Dates Manufacturer Received01/26/2024
03/12/2024
Supplement Dates FDA Received02/15/2024
04/08/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured10/05/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age69 YR
Patient SexMale
-
-